Omalizumab for pediatric allergic asthma: evidence-based insights on efficacy and safety from a meta-analysis of randomized trials
This meta-analysis aimed to synthesize data from English-language randomized controlled trials (RCTs) to evaluate the efficacy and safety of omalizumab in patients aged 6–20 years with allergic asthma, with specific attention to age-stratified outcomes where feasible. Conducted in accordance with the PRISM...